Kinetic mechanisms for overexpression insensitivity and oncogene cooperation

FEBS Letters

Volumn 583, Issue 1, 2009, Pages 93-96

  Legewie, Stefan ^a   Sers, Christine ^b   Herzel, Hanspeter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cooperation; Kinetic modelling; Oncogene; Overexpression

Indexed keywords

RAS PROTEIN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; GENE EXPRESSION; KINETICS; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

CELL TRANSFORMATION, NEOPLASTIC; GENES, RAS; HUMANS; KINETICS; MODELS, BIOLOGICAL; RAS PROTEINS;

EID: 57749200702     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.11.027     Document Type: Article

References (28)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Schubbert S., Shannon K., and Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7 (2007) 295-308
3. Buday L., and Downward J. Epidermal growth factor regulates the exchange rate of guanine nucleotides on p21ras in fibroblasts. Mol. Cell Biol. 13 (1993) 1903-1910
4. Tuveson D.A., et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5 (2004) 375-387
5. Chevallier-Multon M.C., Schweighoffer F., Barlat I., Baudouy N., Fath I., Duchesne M., and Tocque B. Saccharomyces cerevisiae CDC25 (1028-1589) is a guanine nucleotide releasing factor for mammalian ras proteins and is oncogenic in NIH3T3 cells. J. Biol. Chem. 268 (1993) 11113-11118
6. Quilliam L.A., Huff S.Y., Rabun K.M., Wei W., Park W., Broek D., and Der C.J. Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity. Proc. Natl. Acad. Sci. USA 91 (1994) 8512-8516
7. Johnson M.R., Look A.T., DeClue J.E., Valentine M.B., and Lowy D.R. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc. Natl. Acad. Sci. USA 90 (1993) 5539-5543
8. Mangues R., Symmans W.F., Lu S., Schwartz S., and Pellicer A. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene 13 (1996) 1053-1063
9. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., and Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63 (2003) 1981-1989
10. Zhang K., Papageorge A.G., and Lowy D.R. Mechanistic aspects of signaling through Ras in NIH 3T3 cells. Science 257 (1992) 671-674
11. Nielsen K.H., Gredsted L., Broach J.R., and Willumsen B.M. Sensitivity of wildtype and mutant ras alleles to Ras specific exchange factors: identification of factor specific requirements. Oncogene 20 (2001) 2091-2100
12. Stites E.C., Trampont P.C., Ma Z., and Ravichandran K.S. Network analysis of oncogenic Ras activation in cancer. Science 318 (2007) 463-467
13. Markevich N., Moehren G., Kiyatkin A., Hoek J.B., and Kholodenko B.N. Signal processing at the Ras circuit: what shapes the Ras activation patterns. IEE Syst. Biol. 1 (2004) 104-113
14. Elenbaas B., et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15 (2001) 50-65
15. Roose J.P., Mollenauer M., Ho M., Kurosaki T., and Weiss A. Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes. Mol. Cell Biol. 27 (2007) 2732-2745
16. Downward J., Graves J.D., Warne P.H., Rayter S., and Cantrell D.A. Stimulation of p21ras upon T-cell activation. Nature 346 (1990) 719-723
17. Li F., et al. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum. Mol. Genet. 15 (2006) 1921-1930
18. Tian T., Harding A., Inder K., Plowman S., Parton R.G., and Hancock J.F. Plasma membrane nanoswitches generate high-fidelity Ras signal transduction. Nat. Cell Biol. 9 (2007) 905-914
19. Porfiri E., Evans T., Chardin P., and Hancock J.F. Prenylation of Ras proteins is required for efficient hSOS1-promoted guanine nucleotide exchange. J. Biol. Chem. 269 (1994) 22672-22677
20. Scheele J.S., Rhee J.M., and Boss G.R. Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proc. Natl. Acad. Sci. USA 92 (1995) 1097-1100
21. Goldbeter A., and Koshland Jr. D.E. An amplified sensitivity arising from covalent modification in biological systems. Proc. Natl. Acad. Sci. USA 78 (1981) 6840-6844
22. Legewie S., Bluthgen N., Schafer R., and Herzel H. Ultrasensitization: switch-like regulation of cellular signaling by transcriptional induction. PLoS Comput. Biol. 1 (2005) e54
23. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
24. Cuadrado A., Bruder J.T., Heidaran M.A., App H., Rapp U.R., and Aaronson S.A. H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts. Oncogene 8 (1993) 2443-2448
25. Batchelor E., and Goulian M. Robustness and the cycle of phosphorylation and dephosphorylation in a two-component regulatory system. Proc. Natl. Acad. Sci. USA 100 (2003) 691-696
26. Shinar G., Milo R., Martinez M.R., and Alon U. Input output robustness in simple bacterial signaling systems. Proc. Natl. Acad. Sci. USA 104 (2007) 19931-19935
27. Hancock J.F. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4 (2003) 373-384
28. Hornberg J.J., Binder B., Bruggeman F.J., Schoeberl B., Heinrich R., and Westerhoff H.V. Control of MAPK signalling: from complexity to what really matters. Oncogene 24 (2005) 5533-5542